

Send us your news to [evbc@uni-jena.de](mailto:evbc@uni-jena.de).

For more frequent updates, please follow us on Twitter  [EVirusBioinfC](#).

## Selected Publications on SARS-CoV-2 by EVBC Members

SARS-CoV-2 Assessment of Viral Evolution (SAVE) program to provide a real-time risk assessment of SARS-CoV-2 variants potentially impacting transmission, virulence, and resistance to convalescent and vaccine-induced immunity. (Nature: [10.1038/s41586-022-04690-5](#))

Vaccines may lower transmission risk and therefore have a public health benefit beyond the individual protection from severe disease. (Nat Med: [10.1038/s41591-022-01816-0](#))

Unlocking capacities of genomics for the COVID-19 response and future pandemics. (Nat Methods: [10.1038/s41592-022-01444-z](#))

Nearly the entire Delta epidemic in Russia has probably descended from a single import event, or from multiple closely timed imports from a single poorly sampled geographic location. (Virus Evol: [10.1093/ve/veac017](#))

Clinical and immunological findings of 5 primary antibody deficiency patients with severe and fatal COVID-19 and

undetectable specific humoral immune response to SARS-CoV-2. (Front Immunol: [10.3389/fimmu.2022.840126](#))

SARS-CoV-2 has proven itself to be a dangerous new human respiratory pathogen with an unpredictable evolutionary capacity, leading to a risk of future variants too great not to ensure all regions of the world are screened by viral genome sequencing, protected through available and affordable vaccines, and have non-punitive strategies in place for detecting and responding to novel variants of concern. (Cold Spring Harb Perspect Med: [10.1101/cshperspect.a041390](#))

Galaxy workflows for fragment-based virtual screening composed of several widely used open-source tools, including rDock and GROMACS: a case study on the SARS-CoV-2 main protease (J Cheminformatics: [10.1186/s13321-022-00588-6](#))

Fatal cases of COVID-19 in vaccinees were rare and often associated with severe comorbidities or other immunosuppressive conditions. (Mod Pathol: [10.1038/s41379-022-01069-9](#))

 [EVBC publications on SARS-CoV-2 on Pubmed](#)